CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON HM11, D0
Market cap: $19.0B (2/09/2026)
Price: $27.35
Announces Positive Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis (CS) and Reports Financial Results for the Third Quarter Ended December 31, 2025
Investor Presentation
Reports Financial Results for the Second Quarter Ended September 30, 2025, and Provides Business Update
Shareholder votes
Brepocitinib VALOR Phase 3 Study in DM on Track for 2025 Data Readout; Investor Event Highlights
Annual Report to Security Holders
Q2
Q1
FY 2024
Q3
S-3ASR
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities Offered under a Shelf Registration
Definitive Proxy Statement
Additional Proxy Materials
Notice of Proposed Sale of Securities
Amended Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership